Lupin Manufacturing Solutions (LMS), a subsidiary of Lupin Limited, announced a major strategic expansion of its Dabhasa manufacturing facility in India. This move is designed to significantly scale up its peptide building-blocks platform and Contract Development and Manufacturing Organization (CDMO) capabilities. The investment includes a new infrastructure block and two specialized units, bolstering LMS’s capacity to handle complex therapeutics and meet growing global demand for advanced pharmaceutical solutions.
Lupin Manufacturing Solutions Boosts CDMO Capabilities
On March 19, 2026, Lupin Manufacturing Solutions (LMS), a global Contract Research, Development, and Manufacturing Organization (CRDMO) and a subsidiary of Lupin Limited, announced a strategic expansion at its Dabhasa facility in India. This move marks a significant advancement in scaling up the company’s peptide building-blocks platform and its overall CRDMO offerings.
New Infrastructure for Complex Therapeutics
The enhanced infrastructure at Dabhasa features a new block designed to improve existing CRDMO capacities. Crucially, this expansion incorporates capacity across two additional specialized units dedicated to peptide manufacturing. These upgrades are targeted at enabling more advanced development and providing flexible manufacturing options necessary for complex therapeutics, thereby addressing increasing global demand for specialized pharmaceutical solutions.
Executive Commentary on Market Shift
Dr. Abdelaziz Toumi, Chief Executive Officer of Lupin Manufacturing Solutions, emphasized the importance of this expansion in light of industry trends. He stated that as pharmaceutical innovation increasingly focuses on complex modalities, building deep capabilities and execution excellence is paramount. The expansion underscores LMS’s commitment to developing scalable capabilities that support complex development programs, solidifying their role in the global peptide ecosystem.
Given that global drug development is increasingly defined by molecular complexity, such as peptides and biologic Antibody-Drug Conjugates (ADCs), this expansion reinforces LMS’s ability to consistently supply high-quality peptide building blocks, including protected amino acids.
About Lupin Manufacturing Solutions (LMS)
LMS is a wholly owned subsidiary of Lupin Limited and serves as a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and a global CDMO. LMS offers integrated solutions across drug substances, complex chemistry, and advanced modalities like ADCs and peptides. The organization leverages Lupin’s scientific rigor and regulatory expertise to support biopharma innovators from early development through to commercial scale, backed by state-of-the-art facilities and a team of over 250 scientists.
Source: BSE
